← All organizations
Highest phase reached
Phase 4
First clinical trial
Aug 1, 1998First marketed drug
Nov 13, 2013First NDA
Nov 13, 2013Last known activity
Feb 27, 2024
Acquired by AbbVie on Jan 1, 2015
Timeline
Drugs by trial phase (47 distinct, 118 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (17 own, 0 via acquisition)
Phase 2 (26 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Anemia, Refractory
- Anemia, Refractory, with Excess of Blasts
- Astrocytoma
- Brain Neoplasms
- Breast Neoplasms
- Burkitt Lymphoma
- Carcinoid Tumor
- Carcinoma
- Carcinoma, Bronchogenic
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Central Nervous System Neoplasms
- Digestive System Neoplasms
- Disease Progression
- Gastrointestinal Neoplasms
- Glioblastoma
- Glioma
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hematologic Neoplasms
- Hodgkin Disease
- Intestinal Neoplasms
- Kidney Neoplasms
- Laryngeal Neoplasms
- Leukemia
- Leukemia, B-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Leukemia, Prolymphocytic
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Multiple Myeloma
- Myelodysplastic-Myeloproliferative Diseases
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasm Metastasis
- Neoplasms
- Neoplasms by Site
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Nervous System Neoplasms
- Neuroendocrine Tumors
- Neurotoxicity Syndromes
- Oligodendroglioma
- Oropharyngeal Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Philadelphia Chromosome
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Prostatic Neoplasms
- Sarcoma
- Smoldering Multiple Myeloma
- Squamous Cell Carcinoma of Head and Neck
- Syndrome
- Urogenital Neoplasms
- Urologic Neoplasms
- Waldenstrom Macroglobulinemia
Marketed drugs (1)
Recent trials (50)
- NCT05963074CollaboratorPhase 2Feb 27, 2024
- NCT05564052CollaboratorPhase 2/Phase 3Dec 21, 2022
- NCT05431179CollaboratorPhase 3Sep 30, 2022
- NCT04450173CollaboratorPhase 2Dec 1, 2020
- NCT04273139CollaboratorPhase 2Mar 31, 2020
- NCT04212013CollaboratorPhase 3Dec 23, 2019
- NCT04235036CollaboratorPhase 2Dec 16, 2019
- NCT03702725CollaboratorPhase 1Jul 1, 2019
- NCT03703167CollaboratorPhase 1Jan 22, 2019
- NCT03282396CollaboratorPhase 2Nov 30, 2018
- NCT03790332Study directorPhase 1/Phase 2Nov 19, 2018
- NCT03790332Lead sponsorPhase 1/Phase 2Nov 19, 2018
- NCT03646461CollaboratorPhase 2Oct 1, 2018
- NCT03207555CollaboratorPhase 2May 23, 2018
- NCT03422393CollaboratorPhase 1May 1, 2018
Details
- Founded
- Sunnyvale, CA, US Jan 1, 1991
- First NDA
- Nov 13, 2013
- Last known activity
- Feb 27, 2024
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval
Notes
Acquired by Abbvie on 5 Mar 2015